U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Inactive Ingredients in Approved Drug Products Search

Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with M

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
182850 Q3 2022 MANNITOL ORAL POWDER 4663mg Correction
182851 Q4 2022 MANNITOL ORAL POWDER 4352mg Correction
182961 Q4 2022 MAGNESIUM SILICATE ORAL TABLET, COATED PARTICLES 30.00 mg 180mg Deletion
182962 Q4 2022 MAGNESIUM STEARATE BUCCAL TABLET, EXTENDED RELEASE 0.58 mg 1mg Deletion
182963 Q4 2022 MAGNESIUM STEARATE ORAL TABLET, COATED PARTICLES 7.00 mg 42mg Deletion
182964 Q4 2022 MAGNESIUM STEARATE VAGINAL TABLET, FILM COATED 0.40 mg Deletion
182965 Q4 2022 MEDIUM-CHAIN TRIGLYCERIDES ORAL CAPSULE, EXTENDED RELEASE 3.08 mg 5mg Deletion
182966 Q4 2022 METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A ORAL TABLET, COATED PARTICLES 27.90 mg 167mg Deletion
182967 Q4 2022 MICROCRYSTALLINE CELLULOSE BUCCAL TABLET, EXTENDED RELEASE 18.04 mg Deletion
182968 Q4 2022 MICROCRYSTALLINE CELLULOSE ORAL TABLET, COATED PARTICLES 283.60 mg 2269mg Deletion
182969 Q4 2022 MILK PROTEIN CONCENTRATE BUCCAL TABLET, EXTENDED RELEASE 23.00 mg 23mg Deletion
183081 Q3 2022 MAGNESIUM STEARATE VAGINAL INSERT 23.00 mg MDE Replacement
183082 Q4 2022 MAGNESIUM STEARATE VAGINAL INSERT 69mg MDE Replacement
183083 Q3 2022 MANNITOL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 220.50 mg MDE Replacement
183084 Q4 2022 MANNITOL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 658mg MDE Replacement
183085 Q3 2022 METHYLPARABEN ORAL POWDER, FOR SUSPENSION 5.00 mg/ 5.00 ml MDE Replacement
183086 Q4 2022 METHYLPARABEN ORAL POWDER, FOR SUSPENSION 5mg MDE Replacement
183087 Q3 2022 MICROCRYSTALLINE CELLULOSE ORAL TABLET 89.60 mg MDE Replacement
183088 Q4 2022 MICROCRYSTALLINE CELLULOSE ORAL TABLET 460mg MDE Replacement
183089 Q3 2022 MONOBASIC POTASSIUM PHOSPHATE SUBCUTANEOUS INJECTION 0.27 %w/v MDE Replacement
183090 Q4 2022 MONOBASIC POTASSIUM PHOSPHATE SUBCUTANEOUS INJECTION 8mg MDE Replacement
183091 Q3 2022 MONOTHIOGLYCEROL INTRAVENOUS INJECTION, SOLUTION 0.01 %w/v MDE Replacement
183092 Q4 2022 MONOTHIOGLYCEROL INTRAVENOUS INJECTION, SOLUTION 158mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: October 1, 2022
Database Last Updated: October 19, 2022

Back to Top